Cargando…
Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
BACKGROUND: The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has failed in many ways to be as potent in the anti-cancer role as pre-clinical studies would have suggested. This paper traces some aspects of this failure to a compensatory erlotinib-mediated increase in interleuk...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628020/ https://www.ncbi.nlm.nih.gov/pubmed/26543772 http://dx.doi.org/10.1186/s40064-015-1441-5 |